Orbimed Advisors SC 13D/A Beneficial ownership report (amended)

EXHIBIT 1

JOINT FILING AGREEMENT

The undersigned hereby agree that this Amendment No. 13 to Schedule 13D, dated March 4, 2020 (the “Schedule 13D”), with respect to the Ordinary Shares of Ascendis Pharma A/S is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 4^th day of March, 2019.

OrbiMed Advisors LLC
By:	/s/ Carl L. Gordon
	Name:   Carl L. Gordon
	Title:     Member
OrbiMed Capital GP V LLC
By:	OrbiMed Advisors LLC
	its Managing Member
By:	/s/ Carl L. Gordon
	Name:   Carl L. Gordon
	Title:     Member of OrbiMed Advisors LLC
OrbiMed Capital LLC
By:	/s/ Carl L. Gordon
	Name:   Carl L. Gordon
	Title:     Member